93. 原発性胆汁性胆管炎 Primary biliary cholangitis Clinical trials / Disease details
臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04751188 (ClinicalTrials.gov) | October 2, 2020 | 5/2/2021 | A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis | Safety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without Response | Primary Biliary Cirrhosis | Drug: Bezafibrate 200 MG Oral Tablet;Drug: Placebo;Drug: Ursodeoxycholic Acid | Instituto Mexicano del Seguro Social | NULL | Active, not recruiting | 18 Years | 65 Years | All | 11 | Phase 3 | Mexico |
| 2 | NCT04594694 (ClinicalTrials.gov) | October 2, 2019 | 14/7/2020 | Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC | A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid | Primary Biliary Cholangitis | Drug: Obeticholic acid;Drug: Bezafibrate 200 MG;Drug: OCA Placebo;Drug: Bezafibrate 200 mg Placebo;Drug: Bezafibrate 400 MG;Drug: Bezafibrate 400 mg Placebo | Intercept Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 75 | Phase 2 | Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom |